PROPHASE LABS STOCK PLUS
PROPHASE LABS STOCK FREE

PROPHASE LABS STOCK PLUS

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. These returns cover a period from Januthrough August 1, 2022. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. and Morningstar, Inc.Ĭopyright 2022 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606Īt the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Forbes Media, LLC Investor's Business Daily, Inc.

Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Jazz currently has a Zacks Rank of #3 (Hold). This represents a change of +8% from what the company reported a year ago.

JAZZ has returned 5.8% over the past month.įor Jazz, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $4.21.

PROPHASE LABS STOCK FREE

One other stock in the same industry, Jazz Pharmaceuticals ( JAZZ Quick Quote JAZZ - Free Report), finished the last trading session 1.3% lower at $158.30. is a member of the Zacks Medical - Drugs industry. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here > The stock currently carries a Zacks Rank #1 (Strong Buy). So, make sure to keep an eye on PRPH going forward to see if this recent jump can turn into more strength down the road. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. Revenues are expected to be $18.02 million, up 97.2% from the year-ago quarter.Įarnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.įor ProPhase Labs, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +288.9%. ProPhase has also formed a new subsidiary to expand its COVID-19 testing into other countries. The company aims to provide these services directly to the consumer and build a genomics data base to be used for further research. The rise in share price is attributable to positive investor expectations for PRPH’s diagnostics and genomics testing services. This compares to the stock's 14.5% gain over the past four weeks. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. ( PRPH Quick Quote PRPH - Free Report) shares rallied 9.1% in the last trading session to close at $14.15.

Prophase labs stock